OakChart

Denali Therapeutics Inc

DNLIHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:50 PM ET

19.82-0.03 (-0.13%)
2026-11-11 21:50 CET
Market cap
3,181.78 USD m
Revenue, TTM
21.38 USD m
Net income, TTM
-314.42 USD m
Free cash flow, TTM
-449.99 USD m
EPS diluted, TTM
-1.74
P/E
-
Compare

Price

DNLI against its 20, 50 and 200-day averages
2050200beatmiss
17.5020.0022.5025.0027.503.2M6.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DNLIclose 19.8220-day 19.1650-day 19.94200-day 21.2519.8252w high

27.4% under the 52-week high of 27.30 on 9 Jul 2026. 52-week low 15.18 on 11 Nov 2025. Last 15 sessions, 23.2% high to low

Volume 0.32× normal · the line is the 50-bar volume average

Profile

DNLI
52-week range, 38% of the way up
15.1827.30

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

IndexRUT
Employees503
IPODec 08, 2017
Beta1.07
ATR, 14d0.90
Rel volume0.32
Short float9.79%
Insider own6.34%
Inst own96.20%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap3.18B
Enterprise Value2.70B
Income-314.42M
Sales21.38M
Book/sh5.78
Cash/sh3.22
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees503
IPODec 08, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S148.63
P/B3.43
P/C6.16
P/FCF-
EV/EBITDA-
EV/Sales126.13
Quick Ratio5.94
Current Ratio6.21
Debt/Eq0.04
LT Debt/Eq0.03
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.74
EPS next Y-2.26
EPS next Q-0.61
EPS this Y40.96%
EPS next Y-28.78%
EPS next 5Y16.88%
EPS past 3/5Y-4.56% -
Sales past 3/5Y- -
EPS Y/Y TTM40.59%
Sales Y/Y TTM-
EPS Q/Q149.61%
Sales Q/Q-
EarningsNov 03 AMC
EPS/Sales Surpr.236.58% 40.28%

Ownership

Insider Own6.34%
Insider Trans-0.18%
Inst Own96.20%
Inst Trans1.50%
ROA-27.20%
ROE-33.94%
ROIC-33.06%
Gross Margin21.42%
Oper. Margin-2488.14%
Profit Margin-1470.50%
SMA203.48%
SMA50-0.56%
SMA200-6.71%
Trades-

Technical

Shs Outstand160.26M
Shs Float150.12M
Short Float9.79%
Short Ratio9.06
Short Interest14.69M
52W High27.30 -27.38%
52W Low15.18 30.59%
Volatility6.30% 4.68%
ATR (14)0.90
RSI (14)51.69
Beta1.07
Rel Volume0.32
Avg Volume1.62M
Volume511,259

Performance

Perf Week-5.42%
Perf Month7.74%
Perf Quarter-20.13%
Perf Half Y0.12%
Perf YTD20.07%
Perf Year12.77%
Perf 3Y22.22%
Perf 5Y-61.19%
Perf 10Y-
Recom1.15
Target Price36.19
Prev Close19.85
Price19.82
Change %-0.13%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jul 13, 2026ResumedJJP MorganOverweight$29+46.3%
Mar 26, 2026ReiteratedHH.C. WainwrightBuy$32 → $42+111.9%
Feb 24, 2026InitiatedWWolfe ResearchPeer Perform
Jan 07, 2026ResumedUUBSBuy$25+26.1%
Apr 10, 2025UpgradeCCantor FitzgeraldNeutral → Overweight
Mar 07, 2025ResumedMMorgan StanleyOverweight$41 → $33+66.5%
Feb 11, 2025InitiatedDDeutsche BankBuy$31+56.4%
Jan 07, 2025InitiatedRRobert W. BairdOutperform$31+56.4%
Jan 03, 2025InitiatedWWilliam BlairOutperform
Dec 16, 2024UpgradeSStifelHold → Buy$37+86.6%

Peers

Mkt cap
TickerCompanyMkt cap
RGNXRegenxbio Inc567.33M
RAREUltragenyx Pharmaceutical Inc1.69B
ALECAlector Inc402.10M
VYGRVoyager Therapeutics Inc108.90M
ARVNArvinas Inc452.51M
ACADAcadia Pharmaceuticals Inc3.18B
BMRNBiomarin Pharmaceutical Inc11.26B
TAKTakeda Pharmaceutical Co ADR66.57B
BIIBBiogen Inc37.66B
PRTAProthena Corp Plc448.28M

Insider trading

latest 14 of 17
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Chin Peter ScottChief Medical OfficerSep 04 '26Sale22.291,65436,868204,538Sep 09 04:44 PM
Chin Peter ScottOfficerSep 04 '26Proposed Sale22.291,65436,867Sep 04 08:38 PM
Thornberry NancyDirectorSep 02 '26Sale22.9011,439261,92919,686Sep 04 05:02 PM
Schuth Alexander O.COFO and SecretarySep 01 '26Sale23.442,76864,882278,995Sep 03 04:17 PM
NANCY THORNBERRYDirectorSep 02 '26Proposed Sale23.2711,439266,128Sep 02 04:31 PM
ALEXANDER SCHUTHOfficerSep 01 '26Proposed Sale23.762,76865,768Sep 01 04:47 PM
Schuth Alexander O.COFO and SecretaryAug 11 '26Sale25.072,85771,625281,763Aug 13 05:01 PM
Schuth Alexander O.OfficerAug 11 '26Proposed Sale25.072,85771,624Aug 11 05:39 PM
CAROLE HOFormer AffiliateFeb 05 '26Proposed Sale20.2939,490801,394Feb 05 04:14 PM
CAROLE HOFormer AffiliateFeb 04 '26Proposed Sale21.18150,0003,176,970Feb 04 04:16 PM
CAROLE HOFormer AffiliateFeb 03 '26Proposed Sale22.16150,0003,324,060Feb 03 04:47 PM
Watts Ryan J.President and CEOJan 06 '26Sale16.5035,198580,767296,833Jan 08 04:20 PM
Schuth Alexander O.COFO and SecretaryJan 06 '26Sale16.5017,218284,097282,828Jan 08 04:19 PM
Ho CaroleConsultantJan 06 '26Proposed Sale16.5017,218284,097Jan 06 08:28 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
TCAFT. Rowe Price Capital Appreciation Equity ETFAUM: 7.62B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.51B
IBBiShares Biotechnology ETFAUM: 11.36B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-030.370-0.2710.37017.7812.6720
2026Q22026-08-06-0.680-0.513-0.6813.602.1516
2026Q12026-05-07-0.690-0.723-0.6880.002.5718
2025Q42026-02-26-0.730-0.737-0.7330.003.0818
2025Q32025-11-06-0.740-0.748-0.7360.001.3617
2025Q22025-08-11-0.720-0.710-0.7240.007.0517
2025Q12025-05-06-0.780-0.697-0.7770.001.3616
2024Q42025-02-27-0.670-0.799-0.6750.009.2118
2024Q32024-11-06-0.630-0.595-0.6330.006.3015
2024Q22024-08-01-0.590-0.703-0.5870.0010.0015
2024Q12024-05-07-0.680-0.695-0.6810.0014.0216
2023Q42024-02-27-0.860-0.804-0.8640.007.9815
2023Q32023-11-07-0.720-0.810-0.7221.2711.1615
2023Q22023-08-081.300-0.6941.301294.1239.5114
2023Q12023-05-08-0.800-0.701-0.80435.1428.7215
2022Q42023-02-27-0.750-0.788-0.74310.2813.1216

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.070-2.081-2.06726.6831.81
2020FY0.630-1.5390.631335.6692.10
2021FY-2.390-2.265-2.39148.6675.99
2022FY-2.600-2.633-2.597108.46109.51
2023FY-1.060-0.995-1.057330.53337.7
2024FY-2.570-2.778-2.5710.0011.71
2025FY-2.970-2.954-2.9700.002.50
2026FY--1.753--52.65
2027FY--2.258--163.52
2028FY--1.705--319.22
2029FY--1.242--436.15
2030FY--0.319--678.49

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-041813331.7514.0055.34
2026Q4S2026-11-03171022.8010.8075.42
2026Q4S2026-10-30172023.8610.8075.42
2026Q4S2026-10-24171022.8010.8075.42
2026Q4S2026-10-21172022.8010.8075.42
2026Q4S2026-10-141713122.8010.8075.42
2026Q4S2026-10-121714122.7110.8075.42
2026Q4S2026-10-021714122.7110.8075.42
2026Q4S2026-09-191714222.7110.8075.42
2026Q4S2026-09-081715222.7110.8075.42
2026Q4S2026-08-241614222.5610.8075.42
2026Q4S2026-08-101514122.6210.8075.42
2026Q4S2026-08-071513122.349.8975.42
2026Q4S2026-08-04151116.324.2668.48

Estimate history

EPS, annual-5.89-0.391-2.0670.631-2.391-2.597-1.057-2.571-2.969-1.7367
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.633-0.675-0.777-0.724-0.736-0.733-0.688-0.6810.365
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0129.1626.678335.65948.661108.463330.5310021.38
Period201720182019202020212022202320242025TTM
Sales, quarterly00000003.60417.778
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual87.4894.66296.19120.531122.283135.966138.385142.626156.182160.258
Period201720182019202020212022202320242025MRQ
Shares, quarterly143.84142.626145.251145.685146.626156.182158.656159.756160.258
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue21.380.000.00330.53108.4648.66335.6626.68129.16
Cost of Goods Sold Incl. D&A16.8014.817.7916.737.035.61--7.42
Gross Profit4.58-14.81-7.79313.81101.4343.05--121.75
Selling, General and Administrative Excl. Other536.59540.53494.08510.50442.18338.80266.77230.37160.22
Research and Development404.87418.78396.44423.88358.73265.35212.62191.88135.28
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-532.01-555.34-501.88-196.70-340.74-295.7562.72-211.68-38.47
Interest Expense---0.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.00-0.101.308.10
Net Income Before Taxes-314.32-512.44-422.70-145.19-325.97-291.1671.96-197.97-36.24
Income Taxes0.100.100.070.030.02-0.570.82-0.350.00
Consolidated Net Income-314.42-512.54-422.77-145.22-325.99-290.5871.14-197.61-36.24
Net Income From Continuing Operations-314.42-512.54-422.77-145.22-325.99-290.5871.14-197.61-36.24
Net Income-314.42-512.54-422.77-145.22-325.99-290.5871.14-197.61-36.24
EPS (Recurring)-1.64-2.97-2.57-1.06-2.60-2.390.63-2.06-0.33
EPS (Basic, Before Extraordinaries)-1.73-2.97-2.57-1.06-2.60-2.390.65-2.07-0.39
EPS (Diluted)-1.74-2.97-2.57-1.06-2.60-2.390.63-2.07-0.39
EBITDA-515.50-540.53-494.08-179.97-333.71-290.1468.89-203.69-31.06
Non-Operating Income (Expense)217.6942.9079.1751.5114.774.599.1415.0210.33
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense92.8199.6381.2785.4078.8862.2336.7628.0218.79
Price To Earnings Ratio------329.37--
Price To Sales Ratio185.68--8.9232.19111.3828.1262.4314.82
Gross Margin21.42--94.9493.5288.47--94.26
Operating Margin-2,488.14---59.51-314.16-607.7818.69-793.48-29.79
Net Margin-1,470.50---43.94-300.56-597.1521.19-740.74-28.06
Shares Outstanding160.26156.18142.63138.39135.97122.28120.5396.1994.66
Market Capitalization3,181.783,181.782,933.132,965.713,776.995,446.8210,044.331,672.861,961.81

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue17.783.600.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A4.685.492.853.782.953.042.331.85
Gross Profit13.10-1.89-2.85-3.78-2.95-3.04-2.33-1.85
Selling, General and Administrative Excl. Other139.85128.65134.51133.58134.49131.92143.25127.99
Research and Development106.1097.02103.8597.91101.95102.70116.2399.79
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-126.75-130.54-137.36-137.37-137.43-134.96-145.58-129.85
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes70.13-127.55-128.45-128.45-126.90-124.12-132.97-114.69
Income Taxes0.000.000.000.100.000.000.000.07
Consolidated Net Income70.13-127.55-128.45-128.55-126.90-124.12-132.97-114.75
Net Income From Continuing Operations70.13-127.55-128.45-128.55-126.90-124.12-132.97-114.75
Net Income70.13-127.55-128.45-128.55-126.90-124.12-132.97-114.75
EPS (Recurring)0.37-0.68-0.69-0.73-0.74-0.72-0.78-0.67
EPS (Basic, Before Extraordinaries)0.37-0.68-0.69-0.73-0.74-0.72-0.78-0.67
EPS (Diluted)0.37-0.68-0.69-0.73-0.74-0.72-0.78-0.67
EBITDA-122.26-125.14-134.51-133.58-134.49-131.92-143.25-127.99
Non-Operating Income (Expense)196.882.998.918.9210.5310.8412.6115.16
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense22.8622.9123.0923.9525.1425.3925.1619.81
Price To Sales Ratio185.681,336.77------
Gross Margin73.66-52.39------
Operating Margin-712.97-3,622.11------
Net Margin394.45-3,539.21------
Shares Outstanding160.26159.76158.66156.18146.63145.69145.25142.63
Market Capitalization3,181.784,082.023,044.952,578.172,123.002,032.411,974.202,933.13

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments867.88832.331,034.511,336.21865.411,469.70415.36464.30406.23
Short Term Receivables2.181.502.705.0014.930.000.008.550.46
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets30.6030.6126.9331.1016.9025.9614.687.992.92
Total Current Assets900.66864.441,064.141,372.32897.231,495.65430.03480.84409.61
Net Property, Plant & Equipment119.94125.6371.6474.5269.6173.4680.6625.1614.92
Total Investments and Advances101.42360.971.601.50426.9534.2041.39149.3861.70
Other Assets22.8423.1416.5411.9010.370.961.166.610.49
Total Assets1,144.851,374.181,153.921,460.241,404.161,604.28553.23661.98486.72
Short Term Debt Incl. Current Port. of LT Debt9.5512.037.267.325.454.693.670.000.00
Accounts Payable3.3311.149.482.794.781.072.591.892.72
Other Current Liabilities85.4779.0461.24353.81368.0165.9439.0930.8911.45
Total Current Liabilities98.35102.2177.98363.92378.2571.7045.3432.7914.16
Long Term Debt32.7442.2944.9853.0358.5564.1768.860.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.865.07317.8844.1382.356.76
Total Liabilities131.09144.50122.96417.81441.87453.75158.34115.1420.93
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity1,013.761,229.681,030.951,042.43962.291,150.53394.89546.85465.80
Total Shareholders Equity1,013.761,229.681,030.951,042.43962.291,150.53394.89546.85465.80
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity1,013.761,229.681,030.951,042.43962.291,150.53394.89546.85465.80
Total Liabilities & Stockholders Equity1,144.851,374.181,153.921,460.241,404.161,604.28553.23661.98486.72
Book Value Per Share6.498.627.457.677.879.554.115.785.32
Tangible Book Value Per Share6.498.627.457.677.879.554.115.785.32
Full-Time Employees503422445427380291261179130
Price to Book Ratio3.432.222.654.245.678.774.243.58-9.06
Return on Assets-40.69-33.45-11.11-22.76-19.326.59-32.52-6.31-23.27
Return on Equity-45.69-37.40-14.01-32.52-27.519.21-41.97-7.16-24.49
Return on Invested Capital-48.98-33.24-13.50-29.76-28.465.86-42.61-6.63-18.93
Quick Ratio9.168.4613.653.772.3720.869.4814.6728.92
Current Ratio9.168.4613.653.772.3720.869.4814.6728.92

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-314.42-512.54-422.77-145.22-325.99-290.5871.14-197.61-36.24
Depreciation19.2314.817.7916.737.035.616.177.997.42
Other Funds (Non Cash)-103.4884.9850.3560.4398.2794.0050.4433.8716.05
Funds from Operations-398.68-412.75-364.63-68.06-220.69-190.98127.75-155.75-12.78
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-45.510.1516.94-289.93-24.03-20.41288.404.1762.89
Cash from Operating Activities-444.19-412.60-347.69-357.99-244.72-211.39416.15-151.5850.12
Capital Expenditures-41.80-9.50-15.91-12.94-17.83-8.50-3.10-17.92-3.39
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses194.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments-124.85264.78-72.84262.25-123.55-13.13-620.11165.63-284.03
Purchase of Investments-1,002.51-441.26-1,229.96-1,813.70-1,115.04-1,422.94-1,285.47-369.70-557.93
Sale Or Maturity of Investments877.65706.051,157.122,075.95991.491,409.81665.36535.33273.90
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities27.34255.28-88.76249.31-141.39-21.63-623.21147.71-287.42
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock228.83197.38516.6417.82310.6719.35634.756.1997.02
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock228.83197.38516.6417.82310.6719.35634.756.1997.02
Proceedsfrom Stock Options201.29188.93499.250.00296.210.00614.090.0093.02
Issuance or Reduction of Debt, Net-0.08-8.17-32.340.000.000.000.000.000.00
Change in Long Term Debt-0.08-8.17-32.340.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt-0.08-8.17-32.340.000.000.000.000.000.00
Net Financing Active Other Cash Flow200.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities428.75189.22484.3017.82310.6719.35634.756.1997.02
Net Change in Cash11.9131.9047.85-90.86-75.43-213.67427.692.33-140.29
Free Cash Flow-449.99-422.10-363.61-370.93-262.55-219.89413.06-169.5046.72
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow------22.85-40.96
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments516.20710.47987.68867.88848.20898.95
Short Term Receivables18.885.431.602.181.901.40
Inventories26.274.140.000.000.000.00
Other Current Assets30.3633.8933.4730.6032.4934.35
Total Current Assets591.71753.931,022.75900.66882.60934.71
Net Property, Plant & Equipment109.30113.42117.27119.94123.21130.10
Total Investments and Advances509.48232.6366.89101.4227.8081.56
Intangible Assets34.5035.2536.00---
Other Assets11.0522.7323.1222.8422.0119.87
Total Assets1,256.041,157.951,266.021,144.851,055.621,166.24
Short Term Debt Incl. Current Port. of LT Debt10.5110.189.869.559.168.87
Accounts Payable13.7011.8140.383.336.7510.84
Other Current Liabilities71.0568.0959.9285.4774.2471.34
Total Current Liabilities95.2690.08110.1698.3590.1591.06
Long Term Debt24.7327.5030.1932.7435.2437.69
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities209.66205.19199.580.004.0410.44
Total Liabilities329.65322.78339.93131.09129.42139.19
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity926.39835.18926.101,013.76926.201,027.05
Total Shareholders Equity926.39835.18926.101,013.76926.201,027.05
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity926.39835.18926.101,013.76926.201,027.05
Total Liabilities & Stockholders Equity1,256.041,157.951,266.021,144.851,055.621,166.24
Book Value Per Share5.785.235.846.496.327.05
Tangible Book Value Per Share5.575.015.616.496.327.05
Full-Time Employees--507503517486
Price to Book Ratio3.434.412.962.612.061.81
Return on Assets-27.20-44.01-40.04-40.69-39.75-35.90
Return on Equity-33.94-54.93-49.59-45.69-44.44-39.69
Return on Invested Capital7.37-14.79-13.43-12.28-13.20-11.66
Quick Ratio5.948.329.289.169.7910.27
Current Ratio6.218.379.289.169.7910.27

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income70.13-127.55-128.45-128.55-126.90-124.12
Depreciation6.323.572.856.502.953.04
Other Funds (Non Cash)-170.4826.6021.8918.5022.8822.49
Funds from Operations-94.03-97.38-103.71-103.55-101.08-98.58
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-23.410.38-27.505.02-6.2223.29
Cash from Operating Activities-117.44-97.00-131.20-98.54-107.30-75.30
Capital Expenditures-8.21-29.61-2.47-1.521.38-4.28
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses194.000.000.000.000.000.00
Purchase or Sale of Investments-169.60-74.4796.9322.2956.45162.21
Purchase of Investments-355.22-271.50-123.07-252.71-50.630.00
Sale Or Maturity of Investments185.62197.03220.00275.00107.08162.21
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities16.19-104.0894.4620.7757.83157.94
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.6115.0119.06192.150.584.06
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.6115.0119.06192.150.584.06
Proceedsfrom Stock Options0.000.0012.37188.930.000.00
Issuance or Reduction of Debt, Net-0.02-0.02-0.02-0.02-1.36-2.43
Change in Long Term Debt-0.02-0.02-0.02-0.02-1.36-2.43
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.02-0.02-0.02-0.02-1.36-2.43
Net Financing Active Other Cash Flow0.000.00200.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities2.5914.98219.04192.13-0.781.62
Net Change in Cash-98.66-186.10182.30114.36-50.2484.26
Free Cash Flow-118.45-97.81-133.67-100.06-105.92-79.58

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-309.79%14.7M150.1M1.57M
2026-10-1510.34%15.5M149.7M1.56M
2026-09-3010.33%15.5M149.7M1.55M
2026-09-1511.45%17.1M149.7M1.59M
2026-08-3111.12%16.6M149.7M1.65M
2026-08-1412.00%18.0M149.6M1.82M
2026-07-3111.64%17.4M149.8M1.88M
2026-07-1510.78%16.0M148.7M1.89M
2026-06-3010.72%15.9M148.7M1.81M
2026-06-1510.36%15.4M148.7M1.83M
2026-05-2910.08%15.0M148.8M1.77M
2026-05-159.91%14.0M141.6M1.75M
2026-04-3010.46%14.8M141.7M1.70M
2026-04-1510.78%15.3M141.8M1.78M
2026-03-3110.90%15.4M141.5M1.80M
2026-03-1310.08%14.3M141.5M1.58M
2026-02-2710.12%14.3M141.5M1.69M
2026-02-139.76%13.6M139.4M1.63M
2026-01-309.69%13.6M139.9M1.63M
2026-01-1510.62%14.9M139.9M1.55M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call12.505.409.309.605.14210.000.000.867-0.1320.007
call15.003.006.907.003.8430.000.000.819-0.1120.008
call17.500.604.601.622.8631400.000.737-0.0920.010
call20.000.002.751.732.3011630.000.534-0.1070.012
call22.500.000.200.160.77732780.000.166-0.0340.008
call25.000.000.400.171.3733310.000.182-0.0610.009
call30.000.002.200.602.0472.000.000.139-0.0790.007
put12.500.002.150.006.7280.000.00-0.166-0.2890.008
put15.000.002.250.053.9631.000.00-0.223-0.2030.009
put17.500.002.400.201.5421620.00-0.260-0.0870.010
put20.000.450.850.800.62112.00209-0.466-0.1050.012
put22.500.854.903.732.62213.000.00-0.834-0.0320.008
put25.003.107.205.932.95222.000.00-0.880-0.0390.006
put30.008.2012.100.003.6850.000.00-0.912-0.0460.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-09-094Statement of changes in beneficial ownership of securities2026-09-04SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-02144Filing for proposed sale of securities under Rule 144.SEC
2026-09-01144Filing for proposed sale of securities under Rule 144.SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-04SCHEDULE 13G/ASEC
2026-07-288-KCurrent report2026-07-27SEC
2026-07-08SCHEDULE 13G/ASEC
2026-06-188-KCurrent report2026-06-12SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-048-KCurrent report2026-06-03SEC
2026-05-228-KCurrent report2026-05-21SEC
2026-05-15SCHEDULE 13GSEC
2026-05-0710-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-078-KCurrent report2026-05-07SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0900363.68K3
2026-080071.62K1
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-0100864.86K2
2025-120000
2025-110000

Institutional holders

Manager% owned
T. Rowe Price Investment Management, Inc.10.19%
BlackRock, Inc.8.84%
BAILLIE GIFFORD & CO6.96%
STATE STREET CORP4.44%
Temasek Holdings4.39%
VANGUARD PORTFOLIO MANAGEMENT LLC4.08%
VANGUARD CAPITAL MANAGEMENT LLC3.95%
FMR LLC2.84%
GOLDMAN SACHS GROUP INC2.62%
GEODE CAPITAL MANAGEMENT, LLC2.53%

Funds

Fund% owned
T. Rowe Price Capital Appreciation Fund3.13%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.70%
iShares Russell 2000 ETF2.40%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.19%
VANGUARD SMALL-CAP INDEX FUND1.95%
VANGUARD U.S. GROWTH FUND1.68%
SMALLCAP World Fund Inc1.57%
T. Rowe Price Small-Cap Stock Fund, Inc.1.47%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.12%
VANGUARD EXTENDED MARKET INDEX FUND1.09%

OakChart. DNLI. Cached 15 minutes.